Table of Contents
What changed
Reported revenue fell to NZ$62.8k from NZ$360.4k in HY22, an 82.6% decline, but the HY22 line was flagged in the extraction source as "other income" rather than product revenue, so the current period actually represents Rua's first domestic product revenues (received in June). Statutory profit before tax swung from a NZ$3.5m loss to a NZ$0.7m profit, and NPAT moved from a NZ$2.5m loss to a NZ$0.7m profit. Operating cash outflow was essentially flat at NZ$3.7m (versus NZ$3.7m prior), and cash on hand fell 24.5% to NZ$1.7m from NZ$2.3m. Capex stepped down sharply to NZ$46.9k from NZ$310.9k. Inventories rose 65.1% to NZ$137.9k as the company built stock ahead of the German launch.
What matters
- The profit swing is not operational. With revenue of only NZ$62.8k, a reported NZ$0.7m PBT cannot come from trading. The release commentary references "Excluding fair value…", indicating a non-cash fair value movement is doing the work. Operating cash outflow unchanged at NZ$3.7m confirms the underlying burn has not improved.
- Cash runway is the binding constraint. At NZ$1.7m closing cash against a ~NZ$3.7m half-year operating outflow, on current burn the business has well under six months of funding unless German and Polish revenue scales quickly or capital is raised.
- Commercial pipeline is still pre-revenue at scale. Management describes market entry as "tantalisingly close" and Germany as "launch-ready", but no forward orders, contracted revenue, or quantified guidance is disclosed.
Expectations
No stated targets, forward-work backlog, or quantitative guidance were supplied. FY22 full-year revenue was NZ$24.2k, so HY23's NZ$62.8k already exceeds the prior full year, consistent with the company's stated move into commercialisation. However, with only qualitative commentary about the German launch and Polish positioning, the release does not support any view on the slope of the H2 revenue ramp or on when operating cash flow turns. What it does support is that first domestic revenue has been recognised and that inventory has been built for the next launch; what it does not support is any judgement on run-rate economics or gross margin.
Quality of result
Low. The reported profit is almost certainly driven by a non-operating fair value item rather than trading performance — operating revenue of NZ$62.8k cannot generate NZ$0.7m of PBT, and operating cash outflow held at NZ$3.7m. Effective tax was zero this period versus a 29.1% credit in HY22, so PBT is the cleaner comparison, and even on that basis the swing is not a cash-backed operating result. Free cash flow pre-lease was -NZ$3.7m, so FCF/NPAT conversion is sharply negative. Inventory build of NZ$54.4k is strategy-consistent but is a working-capital use, not a release. Very little of this half's reported earnings looks durable.
Unresolved
- What was the specific fair value gain (biological assets, derivative, investment revaluation?) that bridged the reported loss-to-profit swing, and is it likely to reverse?
- What is the funding plan given NZ$1.7m cash against a ~NZ$3.7m half-year burn — equity raise, debt facility, or revenue acceleration assumed?
- What is the expected ramp and gross margin profile for Germany and Poland once launched, and are there any committed orders?
- Given HY22's NZ$360.4k was labelled "other income" in the extraction, what was its nature and why has it not recurred?
- What does segmental or geographic revenue look like now that domestic sales have started?
This briefing cannot assess the specific fair value item driving the profit swing, Rua's funding runway strategy, or the commercial terms of the forthcoming German and Polish launches, because none of these are quantified in the supplied extraction.
Key metrics
| Metric | HY23 | HY22 | Change |
|---|---|---|---|
| Revenue | $62.8m | $360.4m | -82.6% ↓ |
| Net profit after tax | $718.7m | −$2.5b | +129.2% ↑ |
| Net cash inflow from operating activities | −$3.7b | −$3.7b | +1.7% ↑ |
| Operating profit | $630m | −$3.9b | +116.2% ↑ |
| Profit before tax | $718.7m | −$3.5b | +120.7% ↑ |
| Cash and cash equivalents | $1.7b | $2.3b | -24.5% ↓ |
| Total assets | $29.1b | $28b | +3.8% ↑ |
Analytical metrics
| Metric | HY23 | HY22 | Context |
|---|---|---|---|
| Effective tax rate | 0.0% | n/m (loss period) | prior loss period |
| FCF pre-lease | −$3.7b | −$4b | +$328.2m |
| FCF post-lease | −$3.7b | −$4b | +$328.2m |
| FCF / NPAT | -516.2% | 163.9% | complementary conversion metric |
| Capex % revenue | 74.6% | 86.3% | — |
| Capex | −$46.9m | −$310.9m | +$264.1m |
| Gross borrowings | — | $0m | — |
| Payout ratio vs NPAT | 0.0% | — | — |
| Payout ratio vs FCF pre-lease | 0.0% | — | covered |
| ROE (annualised) | 2.7% | -9.3% | Strengthening |
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.
Source-backed analysis from the filing set attached to this briefing.